Please login to the form below

Not currently logged in
Email:
Password:

Pliva finalises German oncology business acquisition

Pliva reveals that its German subsidiary AWD Pharma signed an agreement to acquire ORCA Pharm, a privately owned pharmaceutical company with a presence in the oncology market in that region

Croatia-headquartered Pliva has revealed that its German subsidiary AWD Pharma has signed an agreement to acquire ORCA Pharm, a privately owned pharmaceutical company with a presence in the oncology market in that region.

When the transaction is closed, AWD will pay a fixed purchase price of EUR 21m and up to an additional EUR 13m, based on the achievement of profitability milestones for 2007 and 2008.

Zeljko Covic, President and COO of Pliva, said: "Our acquisition of ORCA pharm provides us with a strategic platform for entering the highly lucrative oncology business in Germany and strongly supports our corporate strategy of focusing on markets with greater barriers-to-entry and thus greater value."

"The acquisition of ORCA pharm and its current product portfolio further supports our commitment to the EU oncology market and strengthens the foothold we have already established through our Czech subsidiary PLIVA Lachema, which focuses on the development, production and distribution of vertically integrated injectable cytostatic products," concluded Covic.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics